文献速递血栓与止血

抗CD38抗体治疗难治性获得性血友病A

Anti-CD38 antibody for refractory acquired hemophilia A.
PubMed 文献 · J Thromb Haemost · 2023-03-20

获得性血友病A(AHA)患者因FVIII抗体导致FVIII活性下降而易于出血,难治性AHA需清除FVIII抑制物。本文首次报告4例对一线和二线治疗难治的AHA患者接受达雷妥尤单抗治疗并获得良好应答,4例患者均未发生严重感染。

要点

  • 达雷妥尤单抗用于4例难治性获得性血友病A患者,均获良好应答。
  • 4例患者均未发生严重感染。
  • 作者据此为难治性获得性血友病A提供了一种新治疗途径。

核心结论

  • 达雷妥尤单抗可使对一线和二线治疗难治的获得性血友病A患者获得良好应答,且4例患者均未发生严重感染。

研究设计与样本

  • 本文报告4例对一线和二线治疗难治的获得性血友病A患者接受达雷妥尤单抗治疗。

主要发现

  • 4例对一线和二线治疗难治的获得性血友病A患者接受达雷妥尤单抗治疗后均获得良好应答。
  • 4例患者均未发生严重感染。

临床怎么用

  • 作者据此为难治性获得性血友病A提供了一种新的治疗途径。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with acquired hemophilia A (AHA) are prone to bleeding symptoms due to decrease in factor (F)VIII activity caused by FVIII antibodies. Risk of severe bleeding in AHA is higher than that of hereditary hemophilia, so clearance of FVIII inhibitors is necessary for treatment, especially in refractory AHA. Daratumumab is currently a popular monoclonal antibody for clearing plasma cells and antibodies and is often used in multiple myeloma. Based on this, we report, for the first time, that 4 patients with AHA who were refractory to first- and second-line therapy were treated with daratumumab and achieved good responses. None of our 4 patients developed serious infections. Thus, we provide a new approach for treating refractory AHA.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Liu W, Liu J, Xue F, et al. Anti-CD38 antibody for refractory acquired hemophilia A. J Thromb Haemost. 2023. PMID: 36940802. doi:10.1016/j.jtha.2023.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。